Stoke Therapeutics’ (STOK) “Buy” Rating Reiterated at Chardan Capital

Stoke Therapeutics (NASDAQ:STOK)‘s stock had its “buy” rating restated by Chardan Capital in a report issued on Wednesday,Benzinga reports. They currently have a $24.00 target price on the stock. Chardan Capital’s target price would indicate a potential upside of 170.57% from the stock’s previous close.

A number of other brokerages also recently issued reports on STOK. HC Wainwright upped their price objective on shares of Stoke Therapeutics from $35.00 to $47.00 and gave the stock a “buy” rating in a research report on Tuesday, February 18th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research note on Tuesday. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Stoke Therapeutics in a research note on Tuesday, December 10th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Stoke Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $23.00.

Stoke Therapeutics Price Performance

NASDAQ:STOK opened at $8.87 on Wednesday. The firm has a 50-day moving average of $9.52 and a 200-day moving average of $11.54. The company has a market cap of $469.82 million, a PE ratio of -4.22 and a beta of 0.99. Stoke Therapeutics has a one year low of $5.60 and a one year high of $17.58.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Monday, March 24th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. On average, equities research analysts expect that Stoke Therapeutics will post -2.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. RTW Investments LP increased its holdings in shares of Stoke Therapeutics by 10.1% in the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock worth $56,512,000 after buying an additional 471,240 shares during the last quarter. Baker BROS. Advisors LP grew its holdings in shares of Stoke Therapeutics by 6.1% during the 4th quarter. Baker BROS. Advisors LP now owns 4,633,838 shares of the company’s stock valued at $51,111,000 after purchasing an additional 265,395 shares during the last quarter. Toronto Dominion Bank bought a new position in shares of Stoke Therapeutics during the 4th quarter valued at $35,001,000. State Street Corp grew its holdings in shares of Stoke Therapeutics by 8.6% during the 3rd quarter. State Street Corp now owns 1,728,888 shares of the company’s stock valued at $21,248,000 after purchasing an additional 137,145 shares during the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Stoke Therapeutics by 2.9% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,350,925 shares of the company’s stock valued at $14,901,000 after purchasing an additional 38,446 shares during the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.